Organon (OGN) Change in Cash (2021 - 2026)
Organon (OGN) posted quarterly Change in Cash of $542.0 million for Q1 2026, up 523.44% year-over-year from $86.9 million in Q1 2025, and up 653.06% on a QoQ basis from -$98.0 million in Q4 2025.
Organon (OGN) Change in Cash (2021 - 2026) Analysis & Trends
Organon (OGN) has reported Change in Cash for 6 consecutive years, with $542.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 523.44% year-over-year to $542.0 million; the TTM figure through Mar 2026 stood at $569.0 million (up 2132.14% YoY), while the FY2025 annual figure was -$101.0 million, down 461.11% from the prior year.
- Change in Cash came in at $542.0 million for Q1 2026 at Organon, up from -$98.0 million in the prior quarter.
- The five-year high for Change in Cash was $542.0 million in Q1 2026, with the low at -$247.0 million in Q1 2023.
- Average Change in Cash over 5 years is $22.3 million, with a median of -$43.0 million recorded in 2022.
- Across the five-year window, Change in Cash plunged 474.42% in 2023 and soared 523.44% in 2026, its largest moves.
- Year by year, Change in Cash stood at $207.0 million in 2022, then soared by 34.78% to $279.0 million in 2023, then plunged by 131.54% to -$88.0 million in 2024, then retreated by 11.36% to -$98.0 million in 2025, then soared by 653.06% to $542.0 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered $542.0 million, -$98.0 million, and $73.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -1.99 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 1.98 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.16 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 5.70 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 542.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 542.00 Mn |
| Dec 31, 2025 | -98.00 Mn |
| Sep 30, 2025 | 73.00 Mn |
| Jun 30, 2025 | 52.00 Mn |
| Mar 31, 2025 | -128.00 Mn |
| Dec 31, 2024 | -88.00 Mn |
| Sep 30, 2024 | 59.00 Mn |
| Jun 30, 2024 | 129.00 Mn |
| Mar 31, 2024 | -118.00 Mn |
| Dec 31, 2023 | 279.00 Mn |
| Sep 30, 2023 | 88.00 Mn |
| Jun 30, 2023 | -133.00 Mn |
| Mar 31, 2023 | -247.00 Mn |
| Dec 31, 2022 | 207.00 Mn |
| Sep 30, 2022 | -46.00 Mn |
| Jun 30, 2022 | -149.00 Mn |
| Mar 31, 2022 | -43.00 Mn |
| Dec 31, 2021 | -271.00 Mn |
| Sep 30, 2021 | 278.00 Mn |
| Jun 30, 2021 | 569.00 Mn |